CO2021018010A2 - Composiciones de diclorfenamida y métodos de uso - Google Patents
Composiciones de diclorfenamida y métodos de usoInfo
- Publication number
- CO2021018010A2 CO2021018010A2 CONC2021/0018010A CO2021018010A CO2021018010A2 CO 2021018010 A2 CO2021018010 A2 CO 2021018010A2 CO 2021018010 A CO2021018010 A CO 2021018010A CO 2021018010 A2 CO2021018010 A2 CO 2021018010A2
- Authority
- CO
- Colombia
- Prior art keywords
- dichlorphenamide
- methods
- compositions
- pharmaceutical composition
- granules
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1611—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Inorganic Chemistry (AREA)
- Organic Chemistry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Physical Education & Sports Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Se provee una composición farmacéutica que comprende: (a) gránulos que comprenden diclorfenamida, o una sal farmacéuticamente aceptable de la misma, y uno o más excipientes intragranulares; y una porción extragranular que comprende por lo menos un modificador de liberación. También se provee un proceso para la preparación y métodos para el uso de la composición farmacéutica.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962863125P | 2019-06-18 | 2019-06-18 | |
PCT/US2020/037169 WO2020257037A1 (en) | 2019-06-18 | 2020-06-11 | Dichlorphenamide compositions and methods of use |
Publications (1)
Publication Number | Publication Date |
---|---|
CO2021018010A2 true CO2021018010A2 (es) | 2022-04-19 |
Family
ID=74040675
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CONC2021/0018010A CO2021018010A2 (es) | 2019-06-18 | 2021-12-28 | Composiciones de diclorfenamida y métodos de uso |
Country Status (12)
Country | Link |
---|---|
US (1) | US20210290542A1 (es) |
EP (1) | EP3972579A4 (es) |
JP (1) | JP2022536955A (es) |
KR (1) | KR20220035119A (es) |
CN (1) | CN114945362A (es) |
AU (1) | AU2020296816A1 (es) |
BR (1) | BR112021025455A2 (es) |
CA (1) | CA3143958A1 (es) |
CO (1) | CO2021018010A2 (es) |
IL (1) | IL289073A (es) |
MX (1) | MX2021016044A (es) |
WO (1) | WO2020257037A1 (es) |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2835702A (en) * | 1956-05-02 | 1958-05-20 | Merck & Co Inc | Benzene 1, 3 disulfonamides possessing diuretic properties |
US3323997A (en) * | 1964-07-16 | 1967-06-06 | Merck & Co Inc | Synergistic diuretic composition |
CN100551363C (zh) * | 2003-10-10 | 2009-10-21 | 生命周期药物公司 | 包含贝特的固体剂型 |
WO2005051325A2 (en) * | 2003-11-25 | 2005-06-09 | Sb Pharmco Puerto Rico Inc. | Carvedilol compositions methods of treatment and delivery |
WO2006119779A2 (en) * | 2005-05-10 | 2006-11-16 | Lifecycle Pharma A/S | A pharmaceutical composition comprising an aldosterone antagonist in form of solid solution |
NZ572207A (en) * | 2006-03-24 | 2012-02-24 | Auxilium Int Holdings Inc | Stabilized compositions containing alkaline labile drugs |
AU2008237246B2 (en) * | 2007-04-05 | 2014-06-05 | University Of Kansas | Rapidly dissolving pharmaceutical compositions comprising pullulan |
US8071557B2 (en) * | 2007-06-13 | 2011-12-06 | Vivus, Inc. | Treatment of pulmonary hypertension with carbonic anhydrase inhibitors |
DE102008059206A1 (de) * | 2008-11-27 | 2010-06-10 | Bayer Schering Pharma Aktiengesellschaft | Pharmazeutische Darreichungsform enthaltend Nifedipin oder Nisoldipin und einen Angiotensin-II Antagonisten und/oder ein Diuretikum |
CA2853965A1 (en) * | 2011-11-03 | 2013-05-10 | Gtx, Inc. | Pharmaceutical compositions of selective androgen receptor modulators and methods of use thereof |
US9433598B2 (en) * | 2015-02-11 | 2016-09-06 | Theravance Biopharma R&D Ip, Llc | (2S,4R)-5-(5′-chloro-2′-fluorobiphenyl-4-yl)-4-(ethoxyoxalylamino)-2-hydroxymethyl-2-methylpentanoic acid |
US20200163911A1 (en) * | 2018-11-27 | 2020-05-28 | Strongbridge Dublin Limited | Methods of treating disease with dichlorphenamide |
-
2020
- 2020-06-11 BR BR112021025455A patent/BR112021025455A2/pt not_active Application Discontinuation
- 2020-06-11 KR KR1020227001229A patent/KR20220035119A/ko unknown
- 2020-06-11 JP JP2021575311A patent/JP2022536955A/ja active Pending
- 2020-06-11 MX MX2021016044A patent/MX2021016044A/es unknown
- 2020-06-11 EP EP20825983.8A patent/EP3972579A4/en not_active Withdrawn
- 2020-06-11 CN CN202080057447.6A patent/CN114945362A/zh active Pending
- 2020-06-11 CA CA3143958A patent/CA3143958A1/en active Pending
- 2020-06-11 WO PCT/US2020/037169 patent/WO2020257037A1/en unknown
- 2020-06-11 AU AU2020296816A patent/AU2020296816A1/en not_active Abandoned
-
2021
- 2021-01-18 US US17/151,405 patent/US20210290542A1/en active Pending
- 2021-12-16 IL IL289073A patent/IL289073A/en unknown
- 2021-12-28 CO CONC2021/0018010A patent/CO2021018010A2/es unknown
Also Published As
Publication number | Publication date |
---|---|
CN114945362A (zh) | 2022-08-26 |
BR112021025455A2 (pt) | 2022-03-03 |
MX2021016044A (es) | 2022-04-06 |
KR20220035119A (ko) | 2022-03-21 |
EP3972579A1 (en) | 2022-03-30 |
WO2020257037A1 (en) | 2020-12-24 |
JP2022536955A (ja) | 2022-08-22 |
CA3143958A1 (en) | 2020-12-24 |
AU2020296816A1 (en) | 2022-02-10 |
US20210290542A1 (en) | 2021-09-23 |
EP3972579A4 (en) | 2023-07-05 |
IL289073A (en) | 2022-02-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO2019002556A2 (es) | Composición farmacéutica | |
CL2020003257A1 (es) | Compuestos antagonistas de pcsk9. | |
CO2018005842A2 (es) | Composición farmacéutica que comprende un potente inhibidor de urat 1 | |
CL2008003431A1 (es) | Compuestos derivados de nucleosidos 2',4' sustituidos; proceso de preparacion de dichos compuestos; composicion farmaceutica que los comprende; su metodo de preparacion; y su uso para el tratamiento y/o la prevencion de cualquier condicion resultante de una infeccion por vhb, vhc o vih. | |
UY27650A1 (es) | Composiciones farmacéuticas para inhibidores de proteasa viral de la hepatitis c | |
CL2007003299A1 (es) | Compuestos derivados de macrociclos, inhibidores del virus de la hepatitis c; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de la hepatitis c. | |
CL2021001753A1 (es) | Compuestos derivados de 2,4-diaminoquinazolina; composición farmacéutica; y su uso para el tratamiento de una infección vírica, cáncer, entre otras (divisional de solicitud 202002253). | |
CL2007003540A1 (es) | Compuestos derivados de macrociclos, inhibidores de la proteasa serina de hepatitis c; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de la hepatitis c. | |
MX2019003099A (es) | Composicion farmaceutica. | |
PA8809601A1 (es) | Combinación anti-retroviral | |
BR112022003434A2 (pt) | Composição de liberação retardada de niclosamida e uso antiviral da mesma | |
BR112019007576A2 (pt) | compostos de bifenil sulfonamida para o tratamento de doenças ou transtornos renais | |
CO6531485A2 (es) | Composiciones farmacéuticas sólidas que contienen un inhibidor de la integrasa | |
DOP2016000254A (es) | Formulaciones farmeceuticas de inhibidor de la quinasa pan-raf, procedimientos para su preparacion, y metodos de uso. | |
CO2023013050A2 (es) | Composiciones de psilocibina, métodos para prepararlas y métodos de uso de estas | |
CL2021002107A1 (es) | Triamtereno o nolatrexed para uso en el tratamiento de fenilcetonuria. | |
CL2020002199A1 (es) | Compuesto de anillo de metillactama y uso farmacéutico del mismo. | |
TR201721505A2 (tr) | Li̇nagli̇pti̇n ve metformi̇n i̇çeren kombi̇nasyon | |
WO2015119924A3 (en) | Fixed-dose combinations of antiviral compounds | |
CO2021018010A2 (es) | Composiciones de diclorfenamida y métodos de uso | |
MX2019003105A (es) | Composicion farmaceutica. | |
MX2019001771A (es) | Composición farmacéutica sólida que comprende el sofosbuvir amorfo. | |
EA201890160A1 (ru) | Твердые фармацевтические композиции для лечения вируса гепатита с | |
DOP2021000028A (es) | Formulaciones de dendrímeros | |
EA201890334A1 (ru) | Твердые фармацевтические композиции для лечения вируса гепатита с |